Challenging Industry Environment Facing CROs, SMOs and Others
First written in FY2017-Q1. 2 of 4 entries say "Restated". Latest entry: FY2019.
No other company in this theme has enough history to compare yet.
- FY2019MaterialisedAnnual report
「Revenue in the Other segment was ¥6,289 million, down 6.8% year on year, due to a decline in orders in the CSO business and lower content sales revenue in the Other businesses, among other factors.」
The decline in CSO orders and other factors affected results in the Other businesses, including the pharmaceutical-related businesses, resulting in lower revenue in the Other segment. - FY2017RestatedAnnual report
「In the CRO business, profit before tax declined year on year due to the impact of a one-off loss arising from the reorganisation of Bell Medical Solutions Co., Ltd. (currently B.I. Medical Co., Ltd.).」
The report continued to describe challenging operating conditions in the pharmaceutical industry and the downward pressure on profit from a one-off loss related to the BMS reorganisation. - FY2017-Q3RestatedAnnual report
「In the CRO business, profit before tax for the quarter declined year on year due to the impact of a one-off loss arising from the reorganisation of Bell Medical Solutions Co., Ltd.」
In addition to challenging operating conditions in the pharmaceutical industry, a one-off loss related to the BMS reorganisation put downward pressure on profit in the Other businesses. - FY2017-Q1First statedAnnual report
「The operating environment in the industries served by each business remained challenging. Revenue in the Other segment was ¥1,847 million, down 0.6% year on year, and profit before tax for the quarter was ¥86 million, down 8.0% year on year.」
The report described the industry environment facing the Other segment as challenging and also noted declines in revenue and profit before tax for the quarter.